Estats Units - anglès - NLM (National Library of Medicine)

akorn - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate 10 mg in 1 ml - atropine sulfate ophthalmic solution, usp 1% is indicated for: atropine sulfate ophthalmic solution should not be used in anyone who has demonstrated a previous hypersensitivity or known allergic reaction to any ingredient of the formulation because it may recur. pregnancy category c: there are no adequate and well-controlled studies of atropine sulfate in pregnant women. animal development and reproduction studies have not been conducted with atropine sulfate. since it is not known whether topically administered atropine sulfate can cause fetal harm, atropine sulfate ophthalmic solution 1% should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. traces of atropine have been found in human milk following administration of atropine solution for injection. because some systemic absorption occurs from topical administration, caution should be exercised when atropine sulfate ophthalmic solution 1% is administered to a nursing woman. due to the potential for systemic

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - somatropin - solution for injection in cartridge - 5.83 milligram(s)/millilitre - somatropin and somatropin agonists; somatropin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

merck serono (ireland) limited - somatropin - solution for injection in cartridge - 8 milligram(s)/millilitre - somatropin and somatropin agonists; somatropin

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

dlrc pharma services limited - atropine sulfate - solution for injection - 100 microgram(s)/millilitre - belladonna alkaloids, tertiary amines; atropine

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - alfentanil hydrochloride, quantity: 1.09 mg (equivalent: alfentanil, qty 1 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride - alfentanil injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil (as hydrochloride) is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil (as hydrochloride) is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil (as hydrochloride) or by adapting the infusion rate.

Aràbia Saudita - anglès - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

alfasan international bv, netherlands - atropine sulphate - solution for injection - 1 mg/ml

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - somatropin 8 mg/ml - solution for injection - 8 mg/ml - active: somatropin 8 mg/ml excipient: citric acid phenol poloxamer sodium hydroxide sucrose water for injection - saizen is indicated for: 1. growth failure in children due to human growth hormone deficiency. 2. growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis. 3.saizen is indicated for replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defined by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfil the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin. 4. growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

Israel - anglès - Ministry of Health

teva israel ltd - atropine sulfate - solution for injection - atropine sulfate 20 mg / 10 ml - atropine - atropine - preanesthetic medication to decrease excessive salivation and secretions of the respiratory tract. treatment of sinus bradycardia, particularly if complicated by hypotension. antidote in poisoning by organophosphorus.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 8 mg/ml - injection, solution - excipient ingredients: phenol; sucrose; citric acid; poloxamer; water for injections; sodium hydroxide - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 8 mg/ml - injection, solution - excipient ingredients: sucrose; poloxamer; sodium hydroxide; water for injections; citric acid; phenol - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).